Rafael Orozco-Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rafael Orozco-Gonzalez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Camila Salazar-Santoliva
One Health Research Group, Universidad de las Americas, Quito 170137, Ecuador
1 shared publication - Daniel Salazar-Duque
Facultad de Medicina, Fundación Universitaria Autónoma de Las Américas, Pereira 660001, Colombia
1 shared publication - Juan M. Hernández-Londoño
Facultad de Medicina, Universidad Alexander von Humboldt, Armenia 630008, Colombia
1 shared publication - Juan Sebastian Izquierdo-Condoy
One Health Research Group, Universidad de Las Américas, Quito 170124, Ecuador
1 shared publication - María-Silvana Rodríguez-Sánchez
Facultad de Medicina, Unidad Central del Valle del Cauca, Cali 763022, Colombia
1 shared publication - Valentina Loaiza-Guevara
Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira 660003, Colombia
1 shared publication
Latest Publications
- Open Access
- 11 October 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1318
Challenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries, where it poses a significant burden. In Latin America, the estimated prevalence of COPD is notably high, but the management and treatment of the disease have progressed slowly. This review examines the current status of inhalation therapy for COPD in Latin America, focusing on pharmacological therapies, inhalation devices, and the potential of advanced drug delivery systems. Pharmacological management predominantly relies on inhaled bronchodilators and corticosteroids, though access to these therapies varies considerably across the region. Inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), play a critical role in effective treatment delivery. However, their usage is often compromised by incorrect technique, low adherence, and limited availability, especially for DPIs. Emerging technologies, including nanoformulations, represent a promising frontier for the treatment of COPD by improving drug delivery and reducing side effects. However, significant barriers, such as high development costs and inadequate infrastructure, hinder their widespread adoption in the region. This review highlights the need for a multifaceted approach to enhance COPD management in Latin America, including optimizing access to existing inhalation therapies, strengthening healthcare infrastructure, improving provider training, and engaging patients in treatment decisions. Overcoming these challenges is crucial to improving COPD outcomes across the region.
- 11 October 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1318
Open AccessChallenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries, where it poses a significant burden. In Latin America, the estimated prevalence of COPD is notably high, but the management and treatment of the disease have progressed slowly. This review examines the current status of inhalation therapy for COPD in Latin America, focusing on pharmacological therapies, inhalation devices, and the potential of advanced drug delivery systems. Pharmacological management predominantly relies on inhaled bronchodilators and corticosteroids, though access to these therapies varies considerably across the region. Inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), play a critical role in effective treatment delivery. However, their usage is often compromised by incorrect technique, low adherence, and limited availability, especially for DPIs. Emerging technologies, including nanoformulations, represent a promising frontier for the treatment of COPD by improving drug delivery and reducing side effects. However, significant barriers, such as high development costs and inadequate infrastructure, hinder their widespread adoption in the region. This review highlights the need for a multifaceted approach to enhance COPD management in Latin America, including optimizing access to existing inhalation therapies, strengthening healthcare infrastructure, improving provider training, and engaging patients in treatment decisions. Overcoming these challenges is crucial to improving COPD outcomes across the region.